Investor Presentaiton
MAX
Financial performance snapshot
Healthcare
Figs in INR Cr
FY19
FY20
FY21
H1 FY22
Amount
% NR
Amount
% NR
Amount
% NR
Amount
% NR
Gross revenue (incl. movement in unbilled)
3,920
4,356
3,881
2,819
Net revenue
3,599
100.0%
4,023
100.0%
3,629
100.0%
2,675
100.0%
Direct costs
1,566
43.5%
1,715
42.6%
1,508
41.6%
1,090
40.3%
Contribution
2,033
56.5%
2,308
57.4%
2,121
58.4%
1,585
59.2%
1,685
46.8%
1,719
42.7%
1,485
40.9%
863
32.3%
Indirect overheads
Operating EBITDA
Loss on fair valuation of pre-merger holding of
Radiant under IND AS 103
Transaction cost
-
ESOP (Equity settled scheme)
One time policy harmonisation impact
348
9.7%
590
14.7%
636
17.5%
722
27.0%
196
5.4%
0.0%
30
0.8%
43
1.1%
48
1.3%
0.0%
27
0.7%
25
0.9%
5
0.1%
0.0%
1992
0.5%
(3)
(0.1%)
1
0.0%
10
0.4%
Movement in fair value of contingent consideration
19
payable and amortisation of contract assets
Exceptional costs: Provision for terminal benefits
under VRS4
8
00
0.3%
Reported EBITDA
299
8.3%
549
13.6%
359
9.9%
679
25.4%
Finance cost (net)
155
4.3%
215
5.3%
187
5.2%
61
2.3%
Depreciation and amortisation
186
5.2%
208
5.2%
216
6.0%
122
4.6%
Profit before tax
(42)
(1.2%)
126
3.1%
(45)
(1.2%)
496
18.5%
Tax
18
Profit after tax
(60)
0.5%
(1.7%)
(3)
(0.1%)
50
1.4%
84
3.1%
129
3.2%
(95)
(2.6%)
412
15.4%
Note:
2.
3.
1. The numbers for the previous periods have been re-casted and regrouped to match with the disclosure in the current period
FY19 financials are pre-IND AS -116 unaudited numbers based on arithmetic total of line items appearing in the pre-merger P&L of Max Healthcare and Radiant Lifecare
Operating EBITDA (pre Ind AS-116) stood at INR 548 Cr in FY20, INR 601 Cr in FY21 and INR 703 Cr in H1 FY22
4.
Provision for VRS expenses relate to Nanavati Max Hospital and represents the likely payout to the employees who have applied under the ongoing scheme so far
27
27View entire presentation